Kanghong Pharmaceutical: Announcement on reaching the exercise conditions for the second exercise period of the 2022 Stock Value-added Rights Incentive Plan
Kanghong Pharmaceutical: Notice on Cancellation of Some Stock Options under the 2021 Stock Option Incentive Plan
Kanghong Pharmaceutical: Announcement of Supervisory Committee Resolutions
Kanghong Pharmaceutical: Legal Opinion of Beijing Commerce (Shenzhen) Law Firm on Cancellation of Part of the Stock Options Incentive Plan of Chengdu Kanghong Pharmaceutical Group Co., Ltd. in 2021 Stock Option Incentive Plan
Kanghong Pharmaceutical: Announcement of Board Resolutions
Kanghong Pharmaceutical: Report for the third quarter of 2024
Kanghong Pharmaceutical: Legal Opinion of Beijing Commerce (Shenzhen) Law Firm on the Achievement of the Enforcement Conditions for the Second Exercise Period of the 2022 Stock Value-added Rights Incentive Plan of Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Kanghong Pharmaceutical: Announcement on the Company\'s Receipt of the Drug Clinical Trial Approval Notice
Kanghong Pharmaceutical: Announcement on Using Own Funds to Purchase Wealth Management Products
Kanghong Pharmaceutical: Announcement on the resignation of the company\'s senior management
Kanghong Pharmaceutical: Investor Relations Activity Record Form for September 12, 2024
Kanghong Pharmaceutical: Announcement on participating in the 2024 Investor Online Group Reception Day and Semi-Annual Report Performance Briefing in the Sichuan Region
Kanghong Pharmaceutical: An indicative announcement on the 2021 Stock Options Incentive Plan granting autonomous exercise rights for part of the third exercise period for the first time
Kanghong Pharmaceutical: An indicative announcement on the 2021 Stock Options Incentive Plan to reserve the right to exercise independently during part of the second exercise period
Kanghong Pharmaceutical: Announcement on the completion of cancellation of some stock options under the 2021 Stock Option Incentive Plan
Kanghong Pharmaceutical: Announcement on Using Own Funds to Purchase Wealth Management Products
Chengdu Kanghong Pharmaceutical Group: The list of eligible options incentive recipients for the first partial exercise period of the 2021 stock options incentive plan and the reserved grants for the second exercise period
Chengdu Kanghong Pharmaceutical Group: Summary of Half-Year Report in 2024.
Chengdu Kanghong Pharmaceutical Group: Peking Tongshang (Shenzhen) Law Firm's legal opinion on the cancellation of part of the stock options and the first grant of part of the stock options in the stock option incentive plan of Chengdu Kanghong Pharmaceutical Group Co., Ltd. in 2021, the achievement of the exercise conditions for the third exercise period, and the reserved grant of part of the stock options for the second exercise period.
Chengdu Kanghong Pharmaceutical Group: Financial Report for the first half of 2024.
No Data
No Data